ImmunityBio, Inc.
IBRX
$7.77
-$0.29-3.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -148.91% | -388.08% | -4.70% | 21.55% | 31.22% |
| Total Depreciation and Amortization | 13.58% | 14.39% | -9.01% | -11.31% | -11.94% |
| Total Amortization of Deferred Charges | -- | -- | -98.00% | -- | -- |
| Total Other Non-Cash Items | 1,003.98% | 793.58% | 108.68% | 149.33% | -22.20% |
| Change in Net Operating Assets | 92.56% | 97.73% | -32.89% | -22.71% | -203.56% |
| Cash from Operations | 16.62% | 12.28% | 17.34% | 30.23% | 20.53% |
| Capital Expenditure | -225.25% | -58.43% | 57.22% | 73.46% | -49.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -590.21% | -669.03% | 272.34% | -366.31% | 70.33% |
| Cash from Investing | -565.77% | -866.53% | 343.09% | -378.88% | 68.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -22,350.00% | -- | -- | 45.45% | 80.95% |
| Issuance of Common Stock | -73.60% | 71,145.45% | -50.11% | 992.13% | 230.08% |
| Repurchase of Common Stock | 0.93% | -481.86% | 26.53% | 49.50% | 35.08% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -74.28% | 22,903.05% | -48.66% | 1,013.59% | 16.06% |
| Foreign Exchange rate Adjustments | -103.95% | 1,320.00% | 171.43% | -609.09% | 533.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -268.22% | 241.41% | -11.13% | -323.45% | 2,727.02% |